Infection of domestic and wild fowl and other birds with influenza A virus. Avian influenza usually does not sicken birds, but can be highly pathogenic and fatal in domestic poultry.
Comprehensive, easy-to-understand information about this condition
How we create this content →Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 3, 2026
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning avian influenza
Updated Feb 18, 2026
Moderna resolves its disagreement with the FDA regarding its mRNA-1010 flu vaccine application, following a Refusal-to-File letter. The company will now pursue approval based on age, with a decision expected in August.
FDA has agreed to review Moderna's application for its mRNA-based flu vaccine following a 'Type A' meeting. This decision marks a significant step forward for the company in its vaccine development efforts.
Disc Medicine faces an unexpected rejection from the FDA, potentially linked to scrutiny over CBER director Vinay Prasad's conduct. Meanwhile, Compass Pathways shares new late-stage data on its psilocybin-based treatment for depression, indicating progress in this emerging therapeutic area.
Moderna's mRNA-1010 flu shot was not reviewed by the FDA, delaying potential advancements in flu vaccine efficacy for Americans. While other countries may benefit from this technology, U.S. patients will have to wait for further developments.
Moderna maintains its financial outlook for 2026 despite recent challenges, including a setback for its influenza vaccine. The company's shares rose as it reassured investors of its growth trajectory.